{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:37Z","timestamp":1787020837937,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystoid macular edema is a rare, vision-threatening side effect of the taxane family of anticancer agents. There is no established treatment or standard treatment protocol for taxane-related cystoid macular edema. Here, we report two cases of taxane-related cystoid macular edema that were treated with topical dorzolamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>In case 1, a 72-year-old Japanese woman with bilateral geographic choroiditis reported for a follow-up visit with a complaint of blurred vision in both eyes for 2\u00a0months after starting nanoparticle albumin-bound paclitaxel chemotherapy for multiple metastases of her breast cancer. Her best-corrected visual acuity had dropped from 1.2 to 0.9 in the right eye and from 1.0 to 0.4 in the left eye. Fundus examination showed no newly active geographic choroiditis lesion, but optical coherence tomography exhibited cystoid macular edema. We suspected taxane-related cystoid macular edema and terminated nanoparticle albumin-bound paclitaxel, and started topical dorzolamide treatment. Cystoid macular edema nearly resolved within 6\u00a0weeks in the right eye and within 10\u00a0weeks in the left eye after starting topical dorzolamide treatment. The resolution of cystoid macular edema without leaving a chorioretinal scar after discontinuation of paclitaxel confirmed our initial diagnosis of taxane-related cystoid macular edema. A few inconspicuous cystoid spaces persisted at the parafovea for a year after dorzolamide treatment ended, but regressed after restarting dorzolamide treatment without any side effects. Best-corrected visual acuity improved to 1.2 in the right eye and 1.0 in the left eye. In case 2, a 70-year-old Japanese man, who received nanoparticle albumin-bound paclitaxel for pancreatic cancer with multiple metastases, developed bilateral cystoid macular edema. Best-corrected visual acuity was 0.3 bilaterally. Cystoid macular edema resolved within 5\u00a0weeks after stopping nanoparticle albumin-bound paclitaxel and starting topical dorzolamide treatment confirming the diagnosis of taxane-related cystoid macular edema. Nine weeks later, best-corrected visual acuity improved to 0.8 in the right eye and 1.0 in the left eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cystoid macular edema in each case resolved within a few months without any side effects using topical dorzolamide and terminating taxane-based chemotherapy. Topical dorzolamide appears to be a safe and effective treatment option for patients with taxane-related cystoid macular edema whose quality of life is threatened by visual disturbances.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-021-02954-8","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T19:06:11Z","timestamp":1626807971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports"],"prefix":"10.1186","volume":"15","author":[{"given":"Mitsuru","family":"Otsubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1344-1641","authenticated-orcid":false,"given":"Reiko","family":"Kinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"issue":"5698","key":"2954_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/277665a0","volume":"277","author":"PB Schiff","year":"1979","unstructured":"Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277(5698):665\u20137.","journal-title":"Nature"},{"issue":"9","key":"2954_CR2","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1021\/ja00738a045","volume":"93","author":"MC Wani","year":"1971","unstructured":"Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325\u20137.","journal-title":"J Am Chem Soc"},{"key":"2954_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","volume":"48","author":"EK Rowinsky","year":"1997","unstructured":"Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 1997;48:353\u201374.","journal-title":"Annu Rev Med"},{"key":"2954_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/OTT.S13836","volume":"4","author":"Y Yamamoto","year":"2011","unstructured":"Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther. 2011;4:123\u201336.","journal-title":"Onco Targets Ther"},{"key":"2954_CR5","unstructured":"ABRAXANE\u00ae [package insert]. Summit, NJ: Celgene Corporation. 2013."},{"issue":"11","key":"2954_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/archopht.126.11.1605","volume":"126","author":"SV Smith","year":"2008","unstructured":"Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol. 2008;126(11):1605\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"2954_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12282-012-0373-y","volume":"22","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Bando H, Hara H, Ito Y, Okamoto Y. Cystoid macular edema induced by nab-paclitaxel. Breast Cancer. 2015;22(3):324\u20136.","journal-title":"Breast Cancer"},{"issue":"2","key":"2954_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/mco.2017.1296","volume":"7","author":"E Bassi","year":"2017","unstructured":"Bassi E, Loizzi V, Furino C, Martino R, Alessio G, Ettore C, et\u00a0al. Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol. 2017;7(2):285\u20137.","journal-title":"Mol Clin Oncol."},{"issue":"26","key":"2954_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011229","volume":"97","author":"CH Shih","year":"2018","unstructured":"Shih CH, Lee YC. Impaired retinal pigment epithelium in paclitaxel-induced macular edema: a case report. Medicine (Baltimore). 2018;97(26): e11229.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2954_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00417-011-1642-8","volume":"250","author":"KM Meyer","year":"2012","unstructured":"Meyer KM, Klink T, Ugurel S, Brocker EB. Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol. 2012;250(3):463\u20134.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2954_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/eye.2012.228","volume":"27","author":"JP Ehlers","year":"2013","unstructured":"Ehlers JP, Rayess H, Steinle N. Topical dorzolamide therapy for taxane-related macular oedema. Eye (Lond). 2013;27(1):102\u20134.","journal-title":"Eye (Lond)"},{"issue":"1","key":"2954_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/ICB.0000000000000433","volume":"12","author":"R Dwivedi","year":"2018","unstructured":"Dwivedi R, Tiroumal S. Possible efficacy of topical dorzolamide in the treatment of paclitaxel-related cystoid macular edema. Retin Cases Brief Rep. 2018;12(1):75\u20139.","journal-title":"Retin Cases Brief Rep."},{"issue":"2","key":"2954_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000477897","volume":"10","author":"T Yokoe","year":"2017","unstructured":"Yokoe T, Fukada I, Kobayashi K, Shibayama T, Miyagi Y, Yoshida A, et\u00a0al. Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review. Case Rep Oncol. 2017;10(2):605\u201312.","journal-title":"Case Rep Oncol"},{"key":"2954_CR14","first-page":"181269","volume":"2015","author":"N Matsuoka","year":"2015","unstructured":"Matsuoka N, Hasebe H, Mayama T, Fukuchi T. Sub-tenon injections of triamcinolone acetonide had limited effect on cystoid macular edema secondary to nanoparticle albumin-bound-paclitaxel (abraxane). Case Rep Ophthalmol Med. 2015;2015:181269.","journal-title":"Case Rep Ophthalmol Med."},{"key":"2954_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-212733","author":"MM Hassall","year":"2016","unstructured":"Hassall MM, Andrew NH. Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema. BMJ Case Rep. 2016. https:\/\/doi.org\/10.1136\/bcr-2015-212733.","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2954_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","volume":"10","author":"IR Edwards","year":"1994","unstructured":"Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10(2):93\u2013102.","journal-title":"Drug Saf"},{"issue":"2","key":"2954_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et\u00a0al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"2954_CR18","unstructured":"Trusopt\u00ae [package insert]. Osaka, Japan: Santen Pharmaceutical Co., Ltd. 2014."},{"issue":"3","key":"2954_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.preteyeres.2011.12.002","volume":"31","author":"RS Molday","year":"2012","unstructured":"Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res. 2012;31(3):195\u2013212.","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"2954_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/01.iae.0000237081.80600.51","volume":"26","author":"MA Apushkin","year":"2006","unstructured":"Apushkin MA, Fishman GA. Use of dorzolamide for patients with X-linked retinoschisis. Retina. 2006;26(7):741\u20135.","journal-title":"Retina"},{"issue":"6","key":"2954_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/bjo.2006.107466","volume":"91","author":"GA Fishman","year":"2007","unstructured":"Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol. 2007;91(6):743\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"3\u20134","key":"2954_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/A:1002496223131","volume":"97","author":"TJ Wolfensberger","year":"1999","unstructured":"Wolfensberger TJ, Dmitriev AV, Govardovskii VI. Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume. Doc Ophthalmol. 1999;97(3\u20134):261\u201371.","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"2954_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1574886313666180828163016","volume":"14","author":"M Kanakis","year":"2019","unstructured":"Kanakis M, Georgalas I, Makatsoris T, Pharmakakis N. Taxane induced cystoid macular edema: case report and integrated pathogenic theory. Curr Drug Saf. 2019;14(1):43\u20137.","journal-title":"Curr Drug Saf"},{"issue":"5","key":"2954_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archopht.125.5.709","volume":"125","author":"MM Joshi","year":"2007","unstructured":"Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol. 2007;125(5):709\u201310.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"2954_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1444-0938.2011.00672.x","volume":"95","author":"CD Georgakopoulos","year":"2012","unstructured":"Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom. 2012;95(2):233\u20136.","journal-title":"Clin Exp Optom"},{"issue":"3","key":"2954_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10792-012-9558-9","volume":"32","author":"TI Kuznetcova","year":"2012","unstructured":"Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol. 2012;32(3):299\u2013304.","journal-title":"Int Ophthalmol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02954-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T19:32:21Z","timestamp":1626809541000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02954-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2954"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02954-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient in case 1 and the patient\u2019s next of kin of in case 2 for publication of the two case reports and any accompanying images. Copies of the written consents are available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial or nonfinancial competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}